| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000005566 |
| Receipt No. | R000006591 |
| Scientific Title | A prospective multicenter clinical study on clinical course and prognosis of idiopathic pulmonary fibrosis |
| Date of disclosure of the study information | 2011/05/07 |
| Last modified on | 2022/03/09 (Ver. 17) |
| Basic information | ||
| Public title | A prospective multicenter clinical study on clinical course and prognosis of idiopathic pulmonary fibrosis | |
| Acronym | A prospective multicenter study on clinical course and prognosis of IPF | |
| Scientific Title | A prospective multicenter clinical study on clinical course and prognosis of idiopathic pulmonary fibrosis | |
| Scientific Title:Acronym | A prospective multicenter study on clinical course and prognosis of IPF | |
| Region |
|
|
| Condition | ||
| Condition | Idiopathic pulmonary fibrosis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The purpose is to examine survival time and the progression-free survival time of IPF. |
| Basic objectives2 | Others |
| Basic objectives -Others | Survival study |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | 1) survival time
2) progression-free survival time 3) onset of acute exacerbation of IPF 4) onset of malignancies including primary lung cancer |
| Key secondary outcomes | 1) changes in pulmonary function test
2) PaO2 at rest and desaturation during 6-min walking test 3) changes of SP-D and KL-6 in sera 4) changes of symptoms |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) The patient who showed an agreement of the participation to the study in a document by free will
2) Sex ; irrespective 3) Age ; 20 and over 4) In-/outpatient ; irrespective 5) The patient who was diagnosed as IPF according to the 4th version of the guideline of clinical diagnostic criteria for idiopathic interstitial pneumonia in Japan and who was authorized by Ministry of Health, Labour and Welfare specific disease 6) The patient who meets the 4th version of the guideline after the authorization |
|||
| Key exclusion criteria | 1) The patient who has the evident cause of interstitial pneumonia such as collagen-vascular diseases, drug, environmental exposure, hypersensitivity pneumonitis, and infection.
2) The patient whom it was judged to be inadequate with HRCT. 3) The patient who has a malignant tumor or who had it with the past. 4) The patient who was judged to be inappropriate as an object of this study due to severe complications. 5) The patient who was judged to be inappropriate as an object of this study by a medical attendant. |
|||
| Target sample size | 300 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Sapporo Medical University School of Medicine | ||||||
| Division name | Department of Respiratory Medicine and Allergology | ||||||
| Zip code | 060-8543 | ||||||
| Address | West 16 South 1, Chuo-ku, Sapporo, 060-8543, JAPAN | ||||||
| TEL | 011-611-2111 | ||||||
| htaka@sapmed.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Sapporo Medical University School of Medicine | ||||||
| Division name | Department of Respiratory Medicine and Allergology | ||||||
| Zip code | 060-8543 | ||||||
| Address | West 16 South 1, Chuo-ku, Sapporo, 060-8543, JAPAN | ||||||
| TEL | 011-611-2111 | ||||||
| Homepage URL | |||||||
| hokkaido-ild@sapmed.ac.jp | |||||||
| Sponsor | |
| Institute | Hokkaido Study Group of Interstitial Lung Diseases |
| Institute | |
| Department | |
| Funding Source | |
| Organization | SHIONOGI & CO., LTD. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Sapporo Medical University Hospital |
| Address | West 16 South 1, Chuo-ku, Sapporo, 060-8543, Japan |
| Tel | 011-611-2111 |
| htaka@sapmed.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | JR札幌病院(北海道)、KKR札幌医療センター(北海道)、NTT東日本札幌病院(北海道)、旭川医科大学病院(北海道)、旭川赤十字病院(北海道)、旭川厚生病院(北海道)、岩見沢市立総合病院(北海道)、王子総合病院(北海道)、小樽協会病院(北海道)、帯広協会病院(北海道)、帯広厚生病院(北海道)、おびひろ呼吸器科内科病院(北海道)、国立病院機構旭川医療センター(北海道)、国立病院機構函館病院(北海道)、国立病院機構北海道医療センター(北海道)、札幌医科大学附属病院(北海道)、札幌厚生病院(北海道)、札幌南三条病院(北海道)、市立旭川病院(北海道)、市立釧路総合病院(北海道)、市立札幌病院(北海道)、市立千歳市民病院(北海道)、市立函館病院(北海道)、市立室蘭総合病院(北海道)、製鉄記念室蘭病院(北海道)、砂川市立病院(北海道)、手稲渓仁会病院(北海道)、天使病院(北海道)、苫小牧市立病院(北海道)、函館五稜郭病院(北海道)、北海道社会保険病院(北海道)、北海道大学病院(北海道)、北海道中央労災病院(北海道)、北海道立苫小牧病院(北海道)、牧田病院(北海道) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | ||
| URL related to results and publications | ||
| Number of participants that the trial has enrolled | 135 | |
| Results | ||
| Results date posted | ||
| Results Delayed |
|
|
| Results Delay Reason | It takes time to analyze the data | |
| Date of the first journal publication of results | ||
| Baseline Characteristics | ||
| Participant flow | ||
| Adverse events | ||
| Outcome measures | ||
| Plan to share IPD | ||
| IPD sharing Plan description | ||
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | Although influence of vital capacity (VC) is suggested as a factor to have an influence on the prognosis of IPF, we will perform the examination about other factors such as disease severity and serum markers in addition. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000006591 |